21st Biosimilars Congregation 2026, 10 Dec 2026

The 21st Biosimilars Congregation 2026 is a conference that examines strategic, clinical, regulatory, manufacturing, and market access developments shaping the global biosimilars landscape.

Key Topics

Trends & Strategies
- Market dynamics, challenges, competitive landscape, and emerging ventures
- Current trends and strategies to access the biosimilar market
- Barriers to formulary inclusion, health equity, and biosimilar market entry
Clinical Development
- Key issues and updates in biosimilar clinical development
Manufacturing
- Reducing costs, optimizing development, and navigating pricing pressures
- Developmental challenges in biosimilar manufacturing
Research & Development (R&D)
- Interchangeability studies and enhancements in R&D models
- Growth in biosimilar R&D, future demand, and success rates
Market Access
- Negotiating access, payer influence, and best practices
- Product launch strategies, sustainability challenges, and market exclusivity
Regulatory
- Regulatory shifts, approval pathways, and interchangeability
- Evolving regulatory framework for biosimilars approval
Real-World Evidence (RWE)
- RWE studies, data sources, and market penetration strategies
- Future evidence requirements for biosimilars registration